IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene ZNF217 Ensembl ENSG00000171940 Chromosome 20 Start 51617011 End 51644208
Description Zinc finger protein 217 [Source:UniProtKB/Swiss-Prot;Acc:O75362]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 13009
     Entrez Gene : 7764
     UCSC : uc002xwq.3
     GeneCards : 13009
     RefSeq : NM_006526
     CCDS : CCDS13443.1
     Uniprot : O75362
     Interpro : O75362
     OMIM : 602967
     GeneTests : ZNF217
     CGAP : ZNF217
     PMID : 9671742

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  32034_at  1.01  6.58e-9  6.94e-8  0.83  1.62e-3  4.72e-3
 HG_U133A  203739_at  1.34  1.75e-50  8.75e-49  0.64  7.17e-20  1.04e-19
 HG_U133_Plus2  203739_at  0.96  3.81e-23  1.24e-21  0.95  6.06e-18  6.67e-17
 Stanford  3760  0.00  0.00e+0  0.00e+0  0.00  0.00e+0  0.00e+0
 Stanford  6027  0.00  0.00e+0  0.00e+0  0.00  0.00e+0  0.00e+0
 Stanford  19337  1.05  2.74e-4  6.30e-3  1.56  1.81e-4  4.17e-3
 Agilent_HS_21.6K  1563  0.21  3.36e-2  1.10e-1  0.23  8.49e-3  3.15e-2

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  203739_at  -0.11  6.72e-1  9.65e-1  -0.09  5.66e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 32034_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 203739_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 203739_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 3760    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 6027    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 19337    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 1563    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
znf217 tumors Among 19 primary OCs examined, moreover, we observed amplification of TGIF2, PTPN1 and ZNF217 in five (26.3%), ten (52.6%), and twelve (63.2%) tumors, respectively. 12417041 Human
znf217 tumor This analysis revealed that genes in the 20q13 chromosomal region, CSE1L, ZNF217, MYBL2, and STK15, were significantly overexpressed in this tumor. 12460888 Human
znf217 residual tumor Significant reciprocal correlation was observed between high levels of CAS and histologic type, FIGO (International Federation of Obstetrics and Gynecology) stage III and grade 3, residual tumor (>2 cm), 20q13.2 (ZNF217 gene) amplification (>4 copies in > 12472286 Human
znf217 residual tumor In univariate analysis, residual tumor, FIGO stage and grade, ZNF217 amplification, and CAS levels predicted outcome (all P < .05). 12472286 Human
znf217 residual tumor In multivariate analysis, stage, grade, amount of residual tumor, and ZNF217 amplification showed independent prognostic value (all P < .05). 12472286 Human
znf217 breast cancers The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. 11245413 Human
znf217 breast cancer Aberrant expression of ZNF217 may be selected for during breast cancer progression because it allows breast cells to overcome senescence and attain immortality. 11245413 Human
znf217 tumors Of the genes amplified in breast cancer, the BTAK gene was amplified in 21%, the MYBL2 gene in 17%, and the ZNF217 gene in 12.5% of the sporadic tumors. 10815905 Human
znf217 breast cancer Of the genes amplified in breast cancer, the BTAK gene was amplified in 21%, the MYBL2 gene in 17%, and the ZNF217 gene in 12.5% of the sporadic tumors. 10815905 Human
znf217 tumors We investigated the copy number of the 20q13.2 region including the ZNF217 oncogene in 17 nonmetastatic colorectal cancers (CRCs), 18 primary CRC tumors with liver metastasis, and 18 metastatic lesions by two-color fluorescence in situ hybridization to ev 10914715 Human
znf217 colorectal cancers We investigated the copy number of the 20q13.2 region including the ZNF217 oncogene in 17 nonmetastatic colorectal cancers (CRCs), 18 primary CRC tumors with liver metastasis, and 18 metastatic lesions by two-color fluorescence in situ hybridization to ev 10914715 Human
znf217 liver metastasis We investigated the copy number of the 20q13.2 region including the ZNF217 oncogene in 17 nonmetastatic colorectal cancers (CRCs), 18 primary CRC tumors with liver metastasis, and 18 metastatic lesions by two-color fluorescence in situ hybridization to ev 10914715 Human
znf217 leukemias The utility of QuMA is demonstrated in assessment of the extent of deletions of chromosome 2 in leukemias arising in radiation-sensitive inbred SJL mice and in analysis of the association of increased copy number of the putative oncogene ZNF217 with reduc 11034080 Human
znf217 ovarian cancer The utility of QuMA is demonstrated in assessment of the extent of deletions of chromosome 2 in leukemias arising in radiation-sensitive inbred SJL mice and in analysis of the association of increased copy number of the putative oncogene ZNF217 with reduc 11034080 Human
znf217 breast carcinoma Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. 9671742 Human
znf217 tumors ZNF217 is centrally located in the 260-kb common region of amplification, transcribed in multiple normal tissues, and overexpressed in all cell lines and tumors in which it is amplified and in two in which it is not. 9671742 Human
znf217 mycosis fungoides Using genomic microarray, we detected oncogene copy number gains of RAF1 (3p25), CTSB (8p22), PAK1 (11q13), and JUNB (19p13) in 5 of 7 cases of mycosis fungoides (MF)/Sezary syndrome (SS) (71%), gains of FGFR1 (8p11), PTPN (20q13), and BCR (22q11) in 4 ca 12393503 Human
znf217 primary carcinomas CCND1 amplifications were associated with the pharyngeal site in primary carcinomas (P < 0.001), whereas amplifications of ZNF217 were less frequent in pharyngeal carcinomas as compared with primary oral and laryngeal carcinomas (P = 0.02). 12649172 Human
znf217 laryngeal carcinomas CCND1 amplifications were associated with the pharyngeal site in primary carcinomas (P < 0.001), whereas amplifications of ZNF217 were less frequent in pharyngeal carcinomas as compared with primary oral and laryngeal carcinomas (P = 0.02). 12649172 Human
znf217 pharyngeal carcinomas CCND1 amplifications were associated with the pharyngeal site in primary carcinomas (P < 0.001), whereas amplifications of ZNF217 were less frequent in pharyngeal carcinomas as compared with primary oral and laryngeal carcinomas (P = 0.02). 12649172 Human
znf217 tumors Amplification of ERBB2, MYC, PPM1D and ZNF217 was detected rarely (1-2% of tumors) indicating a considerably lower amplification frequency than in FBC. 15300811 Human
znf217 colon cancer The candidate oncogene ZNF217 is frequently amplified in colon cancer. 15476264 Human
znf217 colon cancer In this study we have defined the changes in gene copy number of the candidate oncogene ZNF217 during colon cancer development and progression. 15476264 Human
znf217 colon carcinomas The gene copy number of ZNF217 was assessed in 100 colon carcinomas (19 Dukes' A, 42 Dukes' B and 39 Dukes' C), 13 colonic adenomas and 10 normal colon samples. 15476264 Human
znf217 colonic adenomas The gene copy number of ZNF217 was assessed in 100 colon carcinomas (19 Dukes' A, 42 Dukes' B and 39 Dukes' C), 13 colonic adenomas and 10 normal colon samples. 15476264 Human
znf217 colon cancers Of the 100 colon cancers studied, 61 showed some level of amplification of ZNF217, 15 had loss of ZNF217, while 24 were diploid. 15476264 Human
znf217 tumours In this study we have found that ZNF217 amplification is a frequent event in colon cancer and that the extent of its amplification varies markedly between tumours (range 3-13 copies). 15476264 Human
znf217 colon cancer In this study we have found that ZNF217 amplification is a frequent event in colon cancer and that the extent of its amplification varies markedly between tumours (range 3-13 copies). 15476264 Human
znf217 cancers There was a trend toward poorer survival in patients whose cancers had either gain or loss of ZNF217. 15476264 Human
znf217 gastric cancer RESULTS: A group of genes including NCOA6, CYP24A1, PTPN1, and ZNF217 was amplified in gastric cancer. 15701848 Human
znf217 gastric cancer A scoring system based on gene copy changes at chromosome 20 can provide an independent patient grouping system that can distinguish patient recurrence status and survival. 15701848 Human
znf217 breast cancer Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization. 15756435 Human
znf217 breast cancer The amplification of Her2/neu or ZNF217 is closely associated with the stages of breast cancer. 15756435 Human
znf217 breast cancer Her2/neu, ZNF217 and c-MYC were found to have a significantly increased copy number in breast cancer cells. 15756435 Human
znf217 breast cancer In breast cancer progression, c-MYC amplification is an early event, while ZNF217 and Her2/neu amplification may play a role in the later stage of tumor development. 15756435 Human
znf217 tumor In breast cancer progression, c-MYC amplification is an early event, while ZNF217 and Her2/neu amplification may play a role in the later stage of tumor development. 15756435 Human
znf217 breast cancers A proportion of breast cancers acquire genetic alterations at 17q11.2-q12 (HER-2/neu), 20q13.2 (ZNF217 gene) and 17p13.1 (p53). 15868435 Human
znf217 tumors Coexistence of Copy Number Changes of Different Genes (INK4A, erbB-1, erbB-2, CMYC, CCND1 and ZNF217) in Urothelial Tumors. 15897688 Human
znf217 tumors The aim of this study was to establish the frequency of combinatorial and separate copy number changes of INK4A (9p21), erbB-1 (7p11), erbB-2 (17q17-21), CMYC (8q24), CCND1 (11q13) and ZNF217 (20q13) in urothelial tumors; a tissue microarray of 159 urothe 15897688 Human
znf217 bladder tumors The aim of this study was to establish the frequency of combinatorial and separate copy number changes of INK4A (9p21), erbB-1 (7p11), erbB-2 (17q17-21), CMYC (8q24), CCND1 (11q13) and ZNF217 (20q13) in urothelial tumors; a tissue microarray of 159 urothe 15897688 Human
znf217 tumors The most frequent genetic change was deletion of INK4A (60% of aberrant tumors), followed by increased copy number changes of ZNF217 (36%), CCND1 (28%), CMYC (12%) and erbB-1 (4%). 15897688 Human
znf217 ovarian cancers The chromosome 20q harbors genes including TGIF2 (20q11.2-q12), AIB1 (20q12), PTPN1 (20q13.1), ZNF217 (20q13.2), and AURKA (20q13.2-q13.3), which were previously reported to be amplified and overexpressed in ovarian cancers. 15880741 Human
znf217 colon tumors Here a putative oncogene (ZNF217) was evaluated in a series of colon tumors, but the method is applicable to any locus for which a nucleic acid sequence is available. 16028408 Human
znf217 ovarian tumor Amplification of 20q is frequently implicated in both breast and ovarian cancer; this region contains a number of oncogenes including MDM2, ZNF217, and the ovarian tumor marker WFDC2 (alias HE4). 16080959 Human
znf217 breast and ovarian cancer Amplification of 20q is frequently implicated in both breast and ovarian cancer; this region contains a number of oncogenes including MDM2, ZNF217, and the ovarian tumor marker WFDC2 (alias HE4). 16080959 Human
znf217 gastric carcinoma METHODS: Semiquantitative polymerase chain reaction (PCR) was used to determine DNA copies of ZNF217 in the specimens from forty- seven cases with primary gastric carcinoma. 16149004 NA
znf217 gastric cancer The incidence of ZNF217 amplification was 11.36% in gastric cancer. 16149004 Human
znf217 tumor The amplification of ZNF217 was significantly associated with tumor size(P< 0.01) and intestinal type of stomach cancer(P< 0.05). 16149004 Human
znf217 tumor CONCLUSION: Oncogene ZNF217 may play a role in specific tumor types or subtypes of gastric cancer. 16149004 Human
znf217 gastric cancer CONCLUSION: Oncogene ZNF217 may play a role in specific tumor types or subtypes of gastric cancer. 16149004 Human
znf217 gastric carcinoma [Study on amplification of ZNF217 in primary gastric carcinoma] OBJECTIVE: To investigate amplification of zinc finger protein 217(ZNF217) and its association with clinicopathologic parameters in primary gastric carcinoma. 16149004 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.